PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 47 filers reported holding PROQR THRAPEUTICS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $952,000 | -4.7% | 309,700 | 0.0% | 0.00% | – |
| Q4 2017 | $999,000 | -33.5% | 309,700 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $1,502,000 | -6.7% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,610,000 | +3.9% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,549,000 | +2.0% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,518,000 | -26.5% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,066,000 | +37.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,499,000 | -0.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,511,000 | -43.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $2,688,000 | -40.4% | 309,700 | 0.0% | 0.00% | -50.0% |
| Q3 2015 | $4,512,000 | -1.6% | 309,700 | +12.6% | 0.00% | 0.0% |
| Q2 2015 | $4,584,000 | -23.8% | 275,000 | 0.0% | 0.00% | -33.3% |
| Q1 2015 | $6,017,000 | +1.0% | 275,000 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $5,959,000 | +26.1% | 275,000 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $4,727,000 | – | 275,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 2,401,570 | $14,602,000 | 2.94% |
| DAFNA Capital Management LLC | 1,237,400 | $7,523,000 | 2.17% |
| RTW INVESTMENTS, LP | 4,902,785 | $29,809,000 | 0.84% |
| Kerrisdale Advisers, LLC | 453,182 | $2,755,000 | 0.31% |
| COWEN AND COMPANY, LLC | 300,042 | $1,824,000 | 0.30% |
| Artal Group S.A. | 1,259,177 | $7,656,000 | 0.21% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $27,664,000 | 0.07% |
| ALTRINSIC GLOBAL ADVISORS LLC | 221,360 | $1,346,000 | 0.06% |
| FRANKLIN STREET ADVISORS INC /NC | 60,000 | $365,000 | 0.04% |
| JENNISON ASSOCIATES LLC | 2,625,514 | $15,963,000 | 0.01% |